Author: Ryan Allway

CALGARY, April 8, 2019 /CNW/ – Inner Spirit Holdings Ltd. (“Inner Spirit” or “the Company”) (CSE:ISH) today announced that further to the initial investment and strategic partnership with Tilray, Inc. (“Tilray”) (NASDAQ:TLRY) and its wholly owned subsidiary High Park Holdings Ltd. that was announced in December 2018, Tilray has increased its total investment in Inner Spirit to $6 million by providing the Company with a $1.5 million secured short-term loan at a rate of 12.0% per annum.

“This additional investment by Tilray is a testament to the strength of the relationships Spiritleaf has built with our strategic partners. When you add the initial success of our local ownership franchise model, the dozen pending corporate stores at high-traffic locations throughout Alberta, and the additional franchise locations we intend to open across the country, Spiritleaf is well positioned to execute on its business plan,” said Darren Bondar, President and CEO of Inner Spirit.

The Company also provided an update on its operations in Ontario as a new Spiritleaf retail store opened in Kingston, Ontario on April 1, 2019. Store sales have exceeded $230,000 in the first seven days of operation with more than 4,800 customers served. Under the terms of the retail and licensing agreement, Spirit Leaf Inc., which is a wholly owned subsidiary of the Company, receives a retail licensing fee of five percent of sales with an additional one percent contributed to Spiritleaf’s national marketing fund.

Inner Sprit has an additional five Spiritleaf retail franchise stores open and operating in Calgary, Brooks, St. Albert and Lethbridge, Alberta and in Moose Jaw, Saskatchewan with another 70 locations across the country under various stages of permitting and construction.

About Inner Spirit

Inner Spirit is establishing a network of recreational cannabis stores under its Spiritleaf brand. Supporting local entrepreneurs by applying its award-winning franchise and retail models, Inner Spirit has more than 100 franchise agreements in place for potential Spiritleaf locations and plans to operate corporate outlets in certain jurisdictions. The Company is simultaneously developing a diverse portfolio of proprietary quality and curated lifestyle cannabis products positioning the company to be an iconic Canadian brand and the most trusted source for recreational cannabis. More information can be found on Inner Spirit’s website at www.innerspiritholdings.com.

Forward-looking statements

This press release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, “potential”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; the establishment of recreational cannabis stores in Canada; the receipt of necessary licenses and permits to open recreational cannabis stores and the timing thereof; the intention of the Company to open, or license others the right to open, Spiritleaf retail cannabis stores in Ontario; the opening of Spiritleaf-branded franchise and corporate retail cannabis stores in Alberta, Saskatchewan and British Columbia; and the intention to grow the Company’s business and operations. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including but not limited to, the risk that additional stores may not open due to national retail cannabis supply issues;; the risk that the Company or its franchisees are not able to open additional retail cannabis stores in Canada or in Ontario; and other factors outside of the Company’s control. Readers are cautioned that the foregoing list of factors and risks is not exhaustive. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature they involve inherent risks and uncertainties. The Company’s actual results, performance or achievements could differ materially from those expressed in, or implied by, the forward-looking information and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits the Company will derive therefrom. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

SOURCE Inner Spirit Holdings

For further information: Investor Relations, Email: invest@spiritleaf.ca, Phone: 1 (403) 930-9300, www.innerspiritholdings.com

TORONTO, April 8, 2019 /CNW/ – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“Beleave” or the “Company“) is pleased to announce that its wholly-owned subsidiary Beleave Kannabis Corp has commenced sales of cannabis oil products at its licensed facility in Hamilton, Ontario.

Beleave has completed its first wholesale transfer of two bulk lots of cannabis oil to another standard processor license holder, as well as having begun cannabis oil product sales to medicinal patients through its online store https://shop.beleave.com. The Company received authorization from Health Canada to sell cannabis oil products in January 2019.

“We’ve been looking forward to sharing these efforts with our patients and the entire Beleave community. I’m happy to say that the time has finally come,” said Roger Ferreira, Chief Science Officer at Beleave. “Our whole team has been working very hard to ensure we’re delivering on our commitment to produce high-quality products that we can all be proud of. We continue to invest in our research and development pipeline in anticipation of future opportunities in the Canadian cannabis derivatives market.”

Current product offerings available to medicinal patients include a blended and balanced THC/CBD cannabis oil. These high-quality and pure cannabis oil products are being offered to patients in convenient and easy-to-use 30 mL bottles with an applicator – allowing for precise dosing control by the patient. MCT, a non-allergenic, flavourless and odourless oil widely-used for pharmaceutical applications, will be used as the carrier oil for Beleave’s cannabis oil products to assist in the timely delivery and absorption of THC and CBD.

Cannabis oil production is already underway at Beleave’s industrial extraction laboratory using proprietary (patent-pending) methods. This process involves the activation, extraction and purification of THC and CBD using only potable components, without using any organic solvents. In addition to producing oils for Beleave’s own medicinal patients, the Company is actively engaged in contract negotiations to offer the same extraction, processing, packaging and distribution services to other micro and standard processor licensed companies.

“We are very excited and proud of our scientific research team and the quality of the work they’re producing,” said Bill Panagiotakopoulos, Chief Executive Officer at Beleave. “In conjunction with our dried flower products, we feel our company’s success will also rely on the production and processing of oils and derivatives for the adult recreational market, anticipated for later this year. This is another great milestone for Beleave.”

Patent applications submitted for the Company’s processes include a regularly submitted United States patent application (U.S. Patent Application 16/201,547), as well as a Patent Cooperation Treaty (PCT) and International Application (PCT Patent Application PCT/CA2018/051508).

ABOUT BELEAVE INC.

Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets.  Beleave is fully-licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.

Beleave is developing new product lines, including cannabis-infused powder products for 2019 as the recreational market is expected to allow for food and beverage-based cannabis products.  Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Through its majority ownership of Procannmed S.A.S., Beleave is fully licensed to cultivate, produce, and extract medical cannabis in Colombia positioning it to capitalize on exports and the expanding Latin American market. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

SOURCE Beleave Inc.

For further information: Investor Relations Contact: Kevin Keagan, Chief Communications Officer, Phone : 1 (647) 449 – 7352, Email : kkeagan@beleave.com; Media Relations Contact: Grant McLeod, SVP, Regulatory Affairs and General Counsel, Phone : 1 (416) 910 – 3401, Email : gmcleod@beleave.com

KINGSTON, ON, April 5, 2019 /CNW/ – Fire & Flower Holdings Corp. (“Fire & Flower” or the “Company”) (TSXV: FAF), today announced the opening of Brock Street Cannabis Co., the second Fire & Flower branded store in Ontario on April 5, 2019 at 10:00 am local time. Brock Street Cannabis Co. is located at 75 Brock Street, Kingston, Ontario.

The Kingston store will be the eleventh Fire & Flower branded store opened in Canada since the legalization of adult-use cannabis in Canada. It joins stores already opened and operating in Alberta, Saskatchewan and Ottawa, Ontario.

“The opening of the second Fire & Flower branded store in Ontario is another step towards bringing Fire & Flower’s best-in-class retail experience to customers across Canada and is an important step in executing on our aggressive growth plan as one of Canada’s leading adult-use cannabis retailers,” shared Mike Vioncek, Chief Operating Officer of Fire & Flower. “We welcome both those who have consumed cannabis for many years and new consumers who are curious to learn more about this diverse product.”

Fire & Flower shops supply consumers with Health Canada-regulated cannabis products and are staffed by highly-trained Cannistas who help guests understand the available products to ensure a safe and enjoyable cannabis experience. The Company’s operating procedures and security protocols are designed to prevent access by minors and focus on being responsible members of the communities in which the Company operates.

The Kingston store agreement was previously announced by Fire & Flower on February 19, 2019 with Ontario license holder, Brandon Long.

“The Fire & Flower team are truly experts in the emerging area of retail cannabis,” shared Brandon Long. “Their professionalism and strong understanding of retail operations has been instrumental in the opening of the Kingston store.”

About Fire & Flower
Fire & Flower is a leading purpose-built, independent adult-use cannabis retailer poised to capture significant Canadian market share. The Company guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the HiFyre digital platform connects consumers with cannabis products. The Company’s leadership team combines extensive experience in the cannabis industry with strong capabilities in retail operations.

Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc., a licenced cannabis retailer in the provinces of Alberta and Saskatchewan and is a consultant and licensor to Fire & Flower-branded retail locations in province of Ontario.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ( “forward-looking statements”). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “project” and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions “may” or “will” occur. These statements are only predictions.

Forward-looking statements are based on the opinions and estimates of management of the Company at the date the statements are made based on information then available to the Company.  Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements.  Forward-looking statements are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct.

The Company assumes no obligation to publicly update or revise forward-looking statements to reflect new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Fire & Flower Holdings Corp.

For further information: Nathan Mison, Vice President, Government and Stakeholder Relations, nmison@fireandflower.com, 780-953-1106

TORONTO, April 5, 2019 /CNW/ – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“Beleave” or the “Company“) is pleased to announce that it has received a Building Permit and moved forward in the Health Canada Licensing process for its facility in London, Ontario.

In September 2018, Beleave purchased the existing 250,000 sq. ft. greenhouse facility and has since been developing the property. This includes the installation of 10 megawatts of electrical capacity fully serviced by London Hydro, HVAC, equipment, and site engineering exceeding industry standards.

Beleave has invested roughly $8 million in the property to date and, once completed as expected later this year, will provide an additional 115,000 sq. ft. of greenhouse grow space and 11,600 sq. ft. of indoor grow space.

The 85-acre London property is home to 15 acres of outdoor land specifically allocated to cultivation, which is more cost-effective and produces product with higher margins while maintaining quality controls.

In addition, Beleave has been pursuing its license from Health Canada and was notified that it is now at the review and security clearance stage, to be followed by the confirmation of readiness.

The building permit was granted by the City of London April 1, 2019. Health Canada notified the company of its progress on April 2, 2019.

ABOUT BELEAVE INC.

Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully-licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.

Beleave is developing new product lines, including cannabis-infused powder products for 2019 as the recreational market is expected to allow for food and beverage-based cannabis products.  Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Through its majority ownership of Procannmed S.A.S., Beleave is fully licensed to cultivate, produce, and extract medical cannabis in Colombia positioning it to capitalize on exports and the expanding Latin American market. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

SOURCE Beleave Inc.

For further information: Investor Relations Contact: Kevin Keagan, Chief Communications Officer, Phone: 1 (647) 449 – 7352, Email: kkeagan@beleave.com; Media Relations Contact: Grant McLeod, SVP, Regulatory Affairs and General Counsel, Phone: 1 (416) 910 – 3401, Email: gmcleod@beleave.com

CALGARY, April 1, 2019 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) (CSE:HITI) (Frankfurt:2LY), an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, has filed its financial results for the first fiscal quarter of 2019 ending January 31st, the highlights of which are included in this news release. The full set of Condensed Interim Consolidated Financial Statements and Management’s Discussion and Analysis can be viewed by visiting High Tide’s website at www.hightideinc.com, its profile page on SEDAR at www.sedar.com or the Company’s CSE profile page at www.thecse.com.

First Quarter 2019 Financial Highlights

• For the quarter ended January 31, 2019, the total assets of the Company increased by 51% to $39,124, 925 from $25,922,494 as at October 31, 2019.
• High Tide had a working capital surplus of $14,994,180 (October 31, 2018 – $14,919,817), mainly due to the increase in liabilities resulting from expanded operations as the company has begun to operate Canna Cabana and has acquired Grasscity.
• Revenue for the quarter ended January 31, 2019 increased by 83%, to $5,000,688 from $2,737,325 for the same period in the previous year, primarily due to the acquisition of Grasscity, the operations of Canna Cabana which began generating revenue on October 27th, 2018 and new customers in High Tide’s Wholesale Segment.
• Gross margin in the first quarter of 2019 increased by 23%, to $1,789,583 from $1,452,089 in the same period in the prior year, primarily due to the increase in sales volume.
• For the three months ended January 31, 2019, the Company generated a loss of $3,821,515 (2018 – income of $325,496) and had net operating cash outflows of $3,942,631 (2018 – inflows of $202,031). The negative income and cashflows are primarily driven by costs incurred to start High Tide and Canna Cabana (neither of which were operating during this period in the prior year), which resulted in hiring permanent staff for both administration and retail operations, as well as incurring professional fees and increased rent.

First Quarter 2019 Corporate Highlights

• On November 13, 2018, High Tide announced that its wholly-owned subsidiary, RGR Canada Inc. had received from Aurora Cannabis Inc. its largest ever wholesale purchase order for smoking accessories.
• On November 20, 2018, the Company announced that it had obtained a receipt for its final long form prospectus filed with the securities regulatory authorities in the Provinces of Alberta, British Columbia and Ontario.
• On December 13, 2018, High Tide closed the sale of senior unsecured convertible debentures of the Company under the brokered private placement, pursuant to which it issued 10,000 debentures at a price of $1,000 per Debenture to Aurora Cannabis Inc. as well as 1,330 debentures to other participants for gross proceeds of $11,330,000.
• On December 17, 2018, the Company’s common shares commenced trading publicly on the Canadian Securities Exchange under the stock symbol “HITI” at the opening of the market.
• On December 19, 2018, High Tide announced the successful closing its Grasscity acquisition.
• On January 7, 2019, the Company opened its fifth Canna Cabana retail store, situated on 111th Avenue Northwest in Edmonton, Alberta.
• On January 9, 2019, High Tide announced that senior executives of the Company were to be featured speakers at the AltaCorp-ATB 7th Annual Institutional Investor Conference in Toronto, Ontario from January 8-10, 2019, at the Lift & Co. Cannabis Expo Industry Day in Vancouver, British Columbia on Thursday, January 10, 2019 and at the Benzinga Cannabis Capital Conference in Miami, Florida from January 15-16, 2019.
• On January 24, 2019, the Company opened two additional Canna Cabana retail stores in Alberta, the first located at 10831 100 Street in Grande Prairie and the second located at Unit 101, 3342 Parsons Road NW in Edmonton.
• On January 30, 2019, High Tide announced that it had signed letters of intent to acquire two cannabis retail locations in Saskatchewan from two separate vendors.
• On January 31, 2019, the Company announced that it had listed its common shares for trading on the Frankfurt Stock Exchange under the securities identification code “WKN: A2PBPS” and the ticker symbol “2LY”.
• Subsequent to the end of the first fiscal quarter of 2019, in chronological order, High Tide:
  • Was selected by a winner of one of the 25 opportunities to apply for a licence to operate a cannabis retail store as a result of the Alcohol and Gaming Commission of Ontario’s (the “AGCO”) Expression of Interest Application Lottery (the “Lottery”);
  • Was selected to assist with the establishment and operation of a retail cannabis store by a second winner of one of the 25 opportunities to apply for a licence to operate a cannabis retail store as a result of the AGCO’s Lottery;
  • Opened its eighth Canna Cabana retail store, which is located at Unit #116, 5305 Magasin Avenue in the city of Beaumont, Alberta;
  • Opened its ninth Canna Cabana retail store, which is located at #105, 330 10th Street NW in Calgary, Alberta;
  • Opened its tenth Canna Cabana retail store, which is located at 11032 Elbow Drive SW in Calgary, Alberta;
  • Announced its year-end 2018 financial results;
  • Was selected to assist with establishing and operating a retail cannabis store by a third winner of one of only 25 opportunities to apply for an operator’s licence as a result of the AGCO’s Lottery; and
  • Opened its 11th Canna Cabana retail store, which is located at 100 Stockton Avenue in Okotoks, Alberta.

SUMMARY OF KEY FINANCIAL MEASURES
For the three months ended January 31:

SUMMARY OF QUARTERLY MEASURES

About High Tide Inc.

High Tide is an Alberta-based, downstream cannabis corporation focused on the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market, with portfolio subsidiaries including RGR Canada Inc., Famous Brandz Inc., Kush West Distribution Inc., Smoker’s Corner Ltd., Grasscity.com, Canna Cabana Inc. and the majority of KushBar Inc. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9).

Representing the core of High Tide’s business, RGR Canada Inc. is a high-quality and innovative designer, manufacturer and distributor of cannabis accessories. Famous Brandz Inc. is a dominant manufacturer of licensed lifestyle accessories, through partnerships with celebrities and entertainment companies including Snoop Dogg and Paramount Pictures. Famous Brandz products are sold to wholesalers and retailers around the world. Founded in 2009 and approved by the Canadian Franchise Association, Smoker’s Corner Ltd. is among Canada’s largest counter-culture chains with 12 locations. Kush West Distribution is in the process of becoming a cannabis wholesaler in the province of Saskatchewan. Based in Amsterdam since 2000, Grasscity.com is the world’s preeminent and most searchable online retailer of smoking accessories and cannabis lifestyle products with approximately 5.8 million site visits annually. With the deregulation of recreational cannabis for adult use across Canada, Canna Cabana Inc., with 11 current locations, is in the process of becoming a sizeable retail brand with a sophisticated yet playful customer experience, while KushBar Inc. is a retail concept that will also be focused on the valued Canadian cannabis consumer.

For more information about High Tide Inc., please visit www.hightideinc.com and its profile page on SEDAR at www.sedar.com.

Forward-Looking Information

Certain statements in this news release are forward-looking information or forward-looking statements. Such information and statements, referred to herein as “forward-looking statements” are made as of the date of this news release or as of the date of the effective date of information described in this news release, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as “outlook”, “expects”, “intend”, “forecasts”, “anticipates”, “plans”, “projects”, “estimates”, “envisages, “assumes”, “needs”, “strategy”, “goals”, “objectives”, or variations thereof, or stating that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements.

Such forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to the ability of High Tide to execute on its business plan and that High Tide will receive one or multiple licenses from Alberta Gaming, Liquor & Cannabis, British Columbia’s Liquor Distribution Branch or the Saskatchewan Liquor and Gaming Authority permitting it to carry on its Canna Cabana Inc. and KushBar Inc. businesses. High Tide considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that any one or more of the government, industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

The forward‐looking statements contained herein are current as of the date of this news release. Except as required by law, High Tide does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. Any and all forward-looking statements included in this news release are expressly qualified by this cautionary statement, and except as otherwise indicated, are made as of the date of this news release.

SOURCE High Tide Inc.

For further information: please contact Nick Kuzyk, Chief Strategy Officer & SVP Capital Markets at High Tide Inc.; Tel: (403) 265-4207; Email: Nick@HighTideInc.com; Web: www.HighTideInc.com.

TORONTO, April 04, 2019 (GLOBE NEWSWIRE) — Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) is excited to announce that the Company has been selected by the German Federal Institute for Drugs and Medical Devices (“BfArM”), through its German joint venture DEMECAN GmbH, to begin domestic production of medical cannabis for the rapidly growing German patient population. The Company is one of three groups that have been selected and is subject to a review period, after which a final decision will be made no earlier than April 17, 2019.

From the beginning, the market opportunity for medical cannabis in Germany has been a key part of Wayland’s global growth strategy. The Company has always prioritized Germany as one of the most exciting medical cannabis markets in the world given its progressive regulations, rapidly expanding patient population, and insurance coverage for over sixty percent (60%) of prescriptions.

“This is a watershed moment for our operations in Germany as it validates the early entry by our company into that market. I congratulate Ben and his team on the ground in Germany and our partner DEMECAN and thank them for their hard work. We hope and expect to see similar successes in other international markets where Wayland has made similar early entries,” stated Wayland Chairman Paul Pathak.

About Wayland Group

Wayland is a vertically integrated cultivator and processor of cannabis. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a cannabis cultivation, extraction, formulation, and distribution business under federal licenses from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany, Regensdorf, Switzerland and, Allesandria, Piedmont, Italy. Wayland will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, Colombia, and Argentina, in its effort to enhance lives through cannabis.

Forward-Looking Information

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the Company being awarded the license, its abilities to produce medical cannabis domestically in Germany and the rate of growth of the German Market and the European market, as well as that the Company’s German facility will be Wayland’s central European production and distribution site, and that the Company is on unparalleled ground to address the robust growth of the European medical cannabis market. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Such assumptions, risks, uncertainties and other factors include, but are not limited to, that the Company will be awarded the license to produce medical cannabis domestically in Germany, that insurance will continue to be provided to over sixty percent (60%) of prescriptions, the Company’s German facility will be Wayland’s central European production and distribution site and that the Company is on unparalleled ground to address the robust growth of the European medical cannabis market. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Wayland, please visit our website at www.waylandgroup.com.

Contact Information:
Investor Relations
Graham Farrell
VP, Communications
Graham.Farrell@waylandgroup.com
647-643-7665

Media Inquiries: media@waylandgroup.com

Corporate Headquarters (Canada)
Wayland Group Corp. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Wayland (Deutschland) GmbH
c/o Wayland
Max Joseph Str. 7
80333 Munich

VANCOUVER, British Columbia, April 5, 2019 /PRNewswire/ — Sunniva Inc. (“Sunniva”, the “Company”, “we”, “our” or “us”) (CSE: SNN) (OTCQB: SNNVF), a North American provider of cannabis products and services, is pleased to announce preliminary revenue of $14.0 million for the three month period ended March 31, 2019.  This represents a 169% increase over the $5.2 million in revenue generated in the comparative three-month period from 2018. All figures are reported in Canadian dollars ($), unless otherwise indicated.

In California, Sunniva began selling cannabis products in the first three months of 2019 through its wholly-owned subsidiary, CP Logistics, LLC (“CPL”) with preliminary revenue of $10.0 million (USD $7.5 million). Revenue was comprised of product sales from premium flower, vape cartridges and concentrates. In March, Sunniva unveiled its first three in-house brands, Sun Fire, KYNDNESS and Herbella, and announced that additional super premium brands will be launched in conjunction with production from the 325,000 sq. ft. purpose-built greenhouse under construction in Cathedral City, California (the “Sunniva California Campus”).

The Company’s other wholly owned subsidiaries, Full-Scale Distributors, LLC (“FSD”) and Natural Health Services Ltd. (“NHS”), contributed first quarter 2019 revenue of $2.3 million and $1.7 million, respectively.

“In California, we now have the strategic pillars in place to ensure scalability and growth for our newly announced brands and we are very proud of our entire team for the execution and delivery of a very strong first quarter,” said Dr. Anthony Holler, CEO of Sunniva. “Our $14.0 million in revenue during the first quarter is close to the total revenue generated by Sunniva in all of 2018. With strong leadership and operating assets producing premium cannabis products, supported by our recent distribution company acquisition, we continue to demonstrate our ability to achieve significant revenue growth and secure shelf space for our Sunniva brands throughout the state.”

Gross profit margin for the first quarter is expected to be between 30-35% due to operational ramp up costs in California.  However, Sunniva reiterates its 2019 revenue estimate in California through CPL of $72–$78 million (USD $55–$60 million), with an estimated gross margin of 40-50%. This estimate does not include revenue from FSD, the Sunniva California Campus and NHS.

Sunniva will be providing a full corporate update on its Canadian and US operations along with its fourth quarter 2018 and fiscal 2018 financial results to be released on April 29, 2019.   First quarter 2019 financial results will be reported before May 30, 2019.

For more information please visit: www.sunniva.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Sunniva Inc.

Sunniva, through its subsidiaries, is a vertically integrated cannabis company operating in the world’s two largest cannabis markets – California and Canada.  Sunniva is focused on creating sustainable premium cannabis brands supported by our large-scale, purpose-built cGMP designed greenhouse and extraction facilities. We offer a steadfast commitment to safety and quality assurance providing cannabis products free from pesticides, which uniquely positions Sunniva in California as a leading provider of safe, high quality, reproducible products at scale. Through production from Phase One of our strategically positioned 325,000 square foot high technology greenhouse which is nearing completion and our fully operational extraction facility in California, we are launching Sunniva branded products in various product categories and price points including flower, pre-rolls, vape cartridges and premium concentrates.  Sunniva branded products will be showcased within our flagship dispensary located at the greenhouse and our in-house marketing and distribution team will ensure the placement of Sunniva branded products at licensed dispensaries throughout the state. Sunniva’s management and board of directors have a proven track record for creating significant shareholder value both in the healthcare and biotech industries.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”), including, but not limited to, Sunniva’s revenue and gross profit margin projections and the launch of Sunniva’s house of brands and the completion of the Sunniva California Campus.  Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release.  Preliminary Q1 2019 revenues and gross margin and estimated full year 2019 revenues and gross margin is based on current wholesale market price estimates for vape cartridges, disposable pens, concentrates and flower.  Management believes that disclosing its current estimates and expectations regarding Q1 2019 and full-year 2019 revenue and gross margin will better allow investors to understand the current expected growth and development of Sunniva’s business and that such information is particularly useful in the current year given that Sunniva has not previously reported significant revenues. Investors are cautioned that these estimates and expectations may not be appropriate, and should not be used, for other purposes.  Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Sunniva Inc.

Related Links

http://www.sunniva.com

VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) — Harvest Health & Recreation, Inc. (CSE: HARV, OTCQX: HRVSF) (“Harvest”), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced that it has entered into an engagement agreement for a brokered private sale of up to 500,000 convertible debentures (the “Debentures”) of Harvest, at a price of US$1,000 per Debenture, for gross proceeds of US$500 million (the “Offering”). The Offering is intended to be closed in five tranches of 100,000 Debentures per tranche, over a period of not more than 18 months.  The net proceeds of the Offering will be used by Harvest for working capital and general corporate purposes.  The first tranche of the Offering is expected to close on May 1, 2019 and subsequent tranches are issuable at the option of Harvest, subject to certain conditions.  Concurrently with the engagement agreement, Harvest also entered into an agreement with a lead investor (the “Lead Investor”) to subscribe for the full amount of the Offering (the “Agreement”). Pursuant to the Agreement with the Lead Investor, Harvest is entitled, in its discretion, to issue the additional tranches of Convertible Debentures not less than 60 days following the issuance of the immediately preceding tranche.

The Debentures will bear interest at a rate of 7.0% per annum from the closing date of each tranche, payable semi-annually in arrears on June 30 and December 30 of each year. The initial tranche of Debentures will be convertible at the option of the holder to Subordinate Voting Shares of Harvest at a price of $15.38 per Subordinate Voting Share, and each subsequent tranche will be convertible at the option of the holder at a 15% premium to the volume weighted average price (“VWAP”) of the Subordinate Voting Shares on the Canadian Securities Exchange for the five trading day period immediately preceding the closing of the relevant tranche.  Each tranche will mature 36 months from the date of issuance of such tranche.  In addition, Harvest may require that any tranche of Debentures be converted if, at any time after the date that is four months and one day following the issuance of the applicable tranche of Debentures, the daily VWAP of the Subordinate Voting Shares is greater than a 40% premium to the applicable conversion price of a tranche for any 10 consecutive trading day period.

Commenting on the transaction, Harvest CEO Steve White said, “This transaction is fuel for growth to realize our vision of becoming one of the most valuable cannabis companies in the world.  With the recent announcement of our acquisition of Verano Holdings, not only will we have the largest and deepest footprint of licenses in the U.S., we are equally well capitalized to ensure our growth ambitions as a company.”

Jason Vedadi, Executive Chairman of Harvest added, “We realize our position as one of the leaders in the fast-growing U.S. cannabis market and this agreement continues our march towards creating unparalleled shareholder value and building the first truly national cannabis company.”

Upon completion of each of Tranches 1, 2 and 3, warrants (“Warrants”) in an amount equal to 40%, 40% and 20% of the number of Subordinate Voting Shares issuable upon conversion of the first, second and third Tranche of Debentures, respectively, will be issued to the purchasers of such Debentures.  Each Warrant will entitle the holder thereof to purchase one Subordinate Voting Share for a period of 36 months from the date of issue. Warrants issued pursuant to Tranche 1 will, subject to the policies of the CSE, have an exercise price equal to $18.17. Warrants issued pursuant to Tranche 2 and 3 will, subject to the policies of the CSE, have an exercise price equal to a 30% premium to the VWAP for the five trading day period immediately preceding the closing date of the relevant Tranche.

Eight Capital brokered the private placement for Harvest as the lead agent and sole bookrunner.

Closing is subject to conditions that are customary for a transaction of this nature and the engagement letter may be terminated by Eight Capital in certain circumstances. There can be no assurances that the private placement will be completed as proposed or at all.

About Harvest Health and Recreation
Harvest Health & Recreation Inc. is one of the first consistently profitable, vertically integrated cannabis companies with one of the largest footprints in the U.S. Harvest’s complete vertical solution includes industry-leading cultivation, manufacturing, and retail facilities, construction, real estate, technology, operational, and brand building expertise — leveraging in-house legal, HR and marketing teams, along with proven experts in writing and winning state-based applications. The company has more than 680 employees with proven experience, expertise and knowledge of in-house best practices that are drawn upon whenever Harvest enters new markets. Harvest’s executive team is comprised of leaders in finance, compliance, real estate and operations. Since its founding in 2011, Harvest has grown its footprint every year, has been ranked as the third largest cultivator in the U.S. and currently owns licenses for more than 140 facilities across the U.S. Harvest shares timely updates and releases as part of its regular course of business with the media and the interested public. For more information, visit:
https://www.harvestinc.com/.

Forward-looking Statements

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Harvest with respect to future business activities. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding the completion of the offering or any tranche of the offering.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects Harvest management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Harvest believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined Company. This forward-looking information may be affected by risks and uncertainties in the business of Harvest and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Harvest has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Harvest does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

On behalf of the board of directors “Jason Vedadi”

Contact
Alex Howe
Powerplant Global Strategies
alex@powerplantstrategies.com
202-271-7997

DENVER, CO, April 1, 2019 /PRNewswire/ – GrowGeneration Corp. (OTCQX: GRWG), (“GrowGen” or the “Company”) one of the largest chains of specialty hydroponic and organic garden centers, with currently 21 locations, today reported financial results for its fiscal year ended December 31, 2018.

2018 Financial Highlights:

• Revenue of $29.0 million up $14.6 million or 102% over 2017 revenues of $14.4 million.
• Acquired 8 stores, HeavyGardens.com and opened Oklahoma City, OK. location in 2018.
• Gross profit margin percentage, exclusive of inventory valuation adjustments, was 25.2% for 2018 compared to 24.2% for 2017.
• Store operating costs, as a percentage of revenue, have declined 13% from 20.6% for 2017 to 18% for 2018
• Corporate overhead, salaries and general and administrative, declined from 13.4% of revenues for 2017 to 11.2% of revenue for 2018.
• Same Store Sales, in the 4^th quarter increased by 12.4%.
• The Company had $14.6 million in cash and cash equivalents at December 31, 2018.
• As of December 31, 2018, the Company had working capital of $21.6 million compared to working capital of $5.6 million at December 31, 2017.
• The Company raised approximately $12.9 million in equity capital through the issuance of common stock and the exercise of warrants and $9.0 million in convertible debt financing for the year ended December 31, 2018.
• Implemented an ERP computer system, with successful deployments in Colorado, Oklahoma and Maine to date.
• Built a national commercial management team to secure large capital commercial projects.

 2019 Highlights:

• Q1 2019, acquired certain assets and product trademarks from the 3^rd largest hydroponic distributor.
• Q1 2019, we acquired 3 additional stores, in Denver, CO, Palm Springs, CA and Reno, NV.
• Opened stores in Brewer, ME and Tulsa, OK.

Darren Lampert, Co-Founder and CEO, said, “This was our 5th consecutive year of record growth for GrowGeneration, with revenues growing over 100% year over year. We continue to focus on expanding our “just in time” supply chain, through new store openings and acquisitions. GrowGen is now EBITDA profitable, starting in Q1 2019. With our corporate foundation now in place, the company is well positioned to continue 100% year over year growth for several more years. GrowGen is now in 8 states, 21 locations, and services some of the country’s largest commercial multi-state cultivation operators. In Q1 2019, the Company acquired three additional stores and opened 2 stores, which will add an additional $14 million in revenue. Our commercial management team closed over $2 million in commercial capital projects in Q1 and we are projecting over $10 million in new capital projects revenue for the year.  Our acquisition of HeavyGardens.com is the foundation of our e-commerce strategy and our omni-channel shopping experience, connecting all of our customers to our platform. Our purchase of product trademarks, from the 3^rd largest hydroponic distributor, bolsters our ability to supply branded “house” products to our customers.  From trellis netting, plastic pots, organic nutrients, GrowGen will now have a complete line of private label products to offer our customers at great prices. This transaction is expected to have a positive impact on margins and profitability in the near term. Further, the formation of GrowGen Canada and GrowGen Hemp Corp demonstrates our commitment to develop other verticals from all emerging markets in our industry. The Company continues the process of up-listing the Company to a larger exchange. We are forecasting 2019 revenue of $52M–58M and adjusted EBITDA of $.12–$.16 per share for 2019.”

2018 Financial Results:

Net revenue for the year ended December 31, 2018 were approximately $29 million, compared to approximately $14.4 million for the year ended December 31, 2017, an increase of $14.6 million, or 102%. The increase in revenues is due to the addition of 9 new retail stores and one e-commerce site during 2018 for which there were no sales for these retail stores and e-commerce site for the year ended December 31, 2017 and 3 stores opened during various times during 2017 that were open for all of 2018.  Sales in the 9 new stores, the e-commerce site and the 3 stores opened in 2017 were approximately $19.8 million for the year ended December 31, 2018 compared to approximately $2.1 million for the year ended December 31, 2017.

The increase in cost of goods sold was due to the 102% increase in revenues comparing the year ended December 31, 2017 to 2018 primarily due to the increase in the number of stores between 2017 and 2018 as noted in the previous paragraph.

Gross profit was $6.4 million for the year ended December 31, 2018, as compared to $3.3 million for the year ended December 31, 2017, an increase of approximately $3.1 million or 97%. Gross profit as a percentage of sales was 22.2% for the year ended December 31, 2018, compared to 22.8% for the year ended December 31, 2017. The slight decrease in the gross profit percentage was primarily due to the increase in non-cash inventory valuation adjustments of approximately $870,000 in 2018 compared to $201,000 in 2017. Gross profit % net of inventory valuation adjustments was 25.2% for 2018 and 24.2% for 2017.

Store operating costs as a percentage of sales were 18% for the year ended December 31, 2018 compared to 20.6% for the year ended December 31, 2017, a 15% improvement.

Non-Cash corporate overhead, consisting of salaries and general and administrative expenses, declined from 13.4% of revenues for 2017 to 11.2% of revenues for 2018.

While the Company continues to focus on the 7 markets noted below and the growth opportunities that exist in each market, we also are focusing on new store acquisitions, proprietary products, and developing our online sales with HeavyGardens.com and Amazon sales.

Balance Sheet Summary

As of December 31, 2018, we had working capital of approximately $21.6 million, compared to working capital of approximately $5.6 million as of December 31, 2017, an increase of approximately $16 million. The increase in working capital from December 31, 2017 to December 31, 2018 was due primarily to the proceeds from the sale of Common Stock, proceeds for a convertible debt offering and exercise of warrants totaling approximately $21.8 million. At December 31, 2018, we had cash and cash equivalents of approximately $14.6 million. We believe that existing cash and cash equivalents are sufficient to fund existing operations for the next twelve months.

Use of Non-GAAP Financial Information

The Company believes that the presentation of results excluding certain items in “Adjusted EBITDA,” such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with generally accepted accounting principles.

Set forth below is a reconciliation of Adjusted EBITDA to net income (loss):

About GrowGeneration Corp.:

GrowGen owns and operates specialty retail hydroponic and organic gardening stores. Currently, GrowGen has 21 stores, which include 5 locations in Colorado, 6 locations in California, 2 location in Nevada, 1 location in Washington, 3 locations in Michigan, 1 location in Rhode Island, 2 locations in Oklahoma, and 1 location in Maine. GrowGen also operates an online superstore for cultivators, located at HeavyGardens.com. GrowGen carries and sells thousands of products, including organic nutrients and soils, advanced lighting technology and state of the art hydroponic equipment to be used indoors and outdoors by commercial and home growers. Our mission is to own and operate GrowGeneration branded stores in all the major legalized cannabis states in the U.S. and Canada. Management estimates that roughly 1,000 hydroponic stores are in operation in the U.S. By 2020 the market is estimated to reach over $23 billion with a compound annual growth.

Forward Looking Statements:

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent our current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this release. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as “look forward,” “believe,” “continue,” “building,” or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings we make with the United States Securities and Exchange Commission, available at: www.sec.gov, and on our website, at: www.growgeneration.com.

Connect:

• Website: www.GrowGeneration.com
• Facebook: GrowGenerationCorp
• Twitter: @GrowGenOK
• Instagram: @growgen

GROWGENERATION CORP. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

GROWGENERATION CORP. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

SOURCE GrowGeneration

Related Links

www.growgeneration.com

EDMONTON, April 5, 2019 /PRNewswire/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the Company has been selected by the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Federal Institute for Drugs and Medical Devices) as one of three winners in the public tender to cultivate and distribute medical cannabis in Germany. The contract will be formalized at the earliest on April 17, 2019, pending the outcome of an appeal procedure on which a ruling is anticipated by April 10, 2019.

The tender saw 79 companies participating,  with the winners able to establish production in Germany upon the completion of the contract associated with the tender. The selection process was based on the submission of a concept for domestic cannabis production, delivery and pricing. Aurora’s concept, judged on criteria such as facility design, quality, security and logistics, received the highest ranking out of all concepts submitted, validating the Company’s leadership in integrated cultivation, production and delivery.

The Company was awarded the maximum number of 5 of the 13 lots in the tender over a period of four years with a minimum supply of 4000kg total. The cannabis produced will be sold to the German government and supplied to wholesalers for distribution to pharmacies.

“We are very proud to have been selected as one of only three companies by the German government, which is a great achievement by our team,” said Neil Belot, Chief Global Business Development Officer. “Having the highest rated concept is a strong validation of the Aurora Standard cultivation philosophy, as well as of our track record in the delivery of safe and high-quality medical cannabis products to the German system. We commenced delivering dried cannabis flower from Canada to the German market in 2017, and recently added cannabis extracts to our offerings for German patients.  Winning the tender reflects a natural evolution for Aurora, establishing a more prominent local footprint in this important international market with over 82 million people.”

Dr. Florian Holzapfel of Aurora Deutschland GmbH, added, “Being one of the winners in this tender reflects our ability to work with international governments and establish ourselves as a trusted partner in multiple global jurisdictions. Upon finalization of the allotment we will commence with our project to construct a state-of-the-art cannabis production facility to further service German patients with safe, high-quality cannabis.”

Facility

The Company’s concept focused on the construction of a highly secure, state-of-the-art, EU GMP compliant indoor cultivation facility with flexibility for future growth. The new facility will be located at the industrial park in Leuna, Saxony Anhalt, near Leipzig. The Leuna industrial park provides all required industrial and logistical infrastructure required for the operation of the facility, with a considerable labour market to draw from. The facility is designed to have capacity in excess of the tendered amounts to provide flexibility in meeting future growth.

About Aurora 

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland have achieved this level of certification.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc. (CSE:HITI).

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

Neither the TSX, NYSE nor their Regulation Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy of this release.

Terry Booth, CEO
Aurora Cannabis Inc.

Forward-Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”), including, but not limited to, statements with respect to the performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur, and include, but are not limited to statements regarding the formalization of the contract associated with the tender, the  outcome of the appeal procedure,  the construction and completion of the Company’s production facility in Germany,  and  the  production capacity of the facility. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Aurora Cannabis Inc.

Related Links

https://auroramj.com/

LEAMINGTON, ON, April 5, 2019 /PRNewswire/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) today announced that its German subsidiary Aphria Deutschland GmbH (“Aphria Germany“) has been selected by the German Federal Institute for Drugs and Medical Devices (“BfArM“) to receive a license for the domestic cultivation of medical cannabis. The provisional decision announced by BfArM is subject to a mandatory 10-day standstill period for public contracts (the “Standstill“), which permits unsuccessful bidders to challenge the decision before the final contract is signed. BfArM’s decision would grant Aphria 5 of the 13 available lots, each with a minimum annual capacity of 200 kg.

“Aphria is proud to have been selected as a successful applicant in the German tender process, a testament to our high production quality standards,” said Hendrik Knopp, Managing Director of Aphria Germany. “The decision from BfArM is a validation of our strategic approach to supporting the German medical cannabis market, including with high-quality, domestic production to secure vital supply for patients. We are very pleased with our continued business momentum in Germany.”

Since Germany’s Cannabis as Medicines Act was enacted in March 2017, the country’s growing medical cannabis needs, currently estimated at up to 40,000 patients, has been exclusively supplied by imports. Pending the successful completion of the Standstill, Aphria looks forward to supplying German patients with domestically-grown, high-quality medical cannabis.

We Have A Good Thing Growing

About Aphria

Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit: aphria.ca

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations with respect to actual production volumes, expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Aphria Inc.

Related Links

http://aphria.com/

TORONTO, April 04, 2019 (GLOBE NEWSWIRE) — CB2 Insights (“CB2” or the “Company”) (CSE: CBII), a leading provider of predictive analytics tools, data-driven software and comprehensive services across the cannabis value chain, today made its second acquisition announcement in 2019 as it has acquired the assets of Colorado-based medical cannabis clinic group Rae of Sunshine Health Services (“ROSH”) LLC, operating as “Relaxed Clarity”, effective immediately.  This follows the 2017 acquisition of Massachusetts-based Canna Care Docs, the largest multi-state cannabis clinic group in the US and the March 20, 2019 announcement of the agreement to acquire Arizona and Colorado-based MedEval LLC. CB2 continues to acquire clinics as part of its strategy to standardize the capture of clinically-validated patient efficacy data. This new acquisition will help expedite that process and will not only improve CB2’s financial metrics but advance the industry at-large.

Relaxed Clarity operates four clinics in Colorado including Denver, Colorado Springs, Pueblo and Broomfield.  The group was established in 2009 and provides comprehensive medical cannabis evaluations and educational support to approximately 15,000 patients each year.  In 2018, Relaxed Clarity recorded approximately US$1.1 million in revenue.

Terms of the acquisition

Under the terms of the acquisition, CB2 has acquired 100% of the assets of each of ROSH and its subsidiaries for a combination of cash and stock.  Total consideration consisted of a cash payment of US$200,000 and issuance of 500,000 common shares of the Company.  Share consideration was negotiated by the parties based on the Company’s most recent financing price, led by Merida Capital.  Additionally, milestone incentive payments are in place relating to patient growth over the next 12 months and total up to US$100,000 in cash and up to a value of US$300,000 in common shares of the Company.

Subsequent share issuances will be based on the 30-day volume weighted average price of the Company’s shares prior to the date of issuance and all shares will be subject to a minimum hold period of four months plus 1 day from the date of each issuance.

Update on 2019 Revenue and Patient Trajectory

“Based on 2018 revenue results of this acquisition, CB2 Insights is currently on track to achieve at least CA$12.2 million in revenue for 2019,” said Prad Sekar, CEO, CB2 Insights. “We have an active pipeline of acquisition targets and along with organic growth within our existing operations, we anticipate achieving our stated 2019 revenue goal of more than CA$20 million, for year-over-year growth of more than 80% compared to 2018.”

At the close of 2018, CB2 Insights was collecting clinically-validated evaluation data through its business units of approximately 65,000 patients annually.  As a result of this announcement, combined with the pending acquisition of MedEval LLC, the Company projects its annualized patient count to increase to approximately 80,000 patient evaluations on an annualized basis.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare.  We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands.  Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information please visit www.cb2insights.com.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding results following the acquisition of Relaxed Clarity including Relaxed Clarity’s expected revenue, contribution to financial performance and patient evaluations, and the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein. 

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Primary Contact
Dan Thompson
Chief Marketing Officer

1.416.670.9316

For Investor Inquiries
Sophic Capital
1.647.362.8286


For Media Inquiries:
KCSA Strategic Communications

BOCA RATON, April 02, 2019 (GLOBE NEWSWIRE) — Stem Holdings Inc. is pleased to announce it has executed a definitive agreement dated March 29, 2019 to acquire Western Coast Ventures Inc. WCV has a working capital surplus of approximately $2,000,000 and has negotiated a joint venture with ILCA Holdings, Inc. ILCA has been issued a limited Conditional Use Permit for a Marijuana Production Facility by the City of San Diego, California, which will only be granting a total of 40 MPFs. The consideration for the acquisition is expected to be 2,000,000 shares of Stem’s common stock, having a value of approximately $3,500,000 based on Stem’s closing trading price on March 29, 2019. After giving effect to the closing of the acquisition of WCV and the previously announced acquisition of South African Ventures, Inc., the former shareholders of WCV will own approximately 7.3% of the issued and outstanding shares of Stem. The acquisition of WCV is expected to be completed on or around April 12, 2019.

The JV will consist of its own management team and with the personnel, expertise, and other resources necessary to construct the MPF. It is agreed that WCV will have a 51% interest in the JV, for an aggregate purchase price of $1,500,000. ILCA will hold the remaining 49% interest in the JV. ILCA previously invested $500,000 in the build-out and initial MPF permitting process. Stem anticipates the JV will finance the cost of construction of the MPF, estimated at $3.5 million, with its cash on hand and other non-dilutive sources of financing. The construction of the facility has begun and is estimated to be completed during the fourth quarter of 2019.

Upon issuance of the final MPF permit and the completed construction, the JV will: (1) operate an advanced cannabis facility to grow and cultivate cannabis; (2) manufacture cannabis-derived products; and (3) distribute cannabis and cannabis-derived products state-wide throughout California.

“With a population of 39 million and the fifth largest GDP in the world, California’s cannabis market is an unparalleled state market which makes it a critical location for Stem’s expansion,” states Adam Berk, CEO of Stem. “The agricultural, production and distribution expertise that both Stem and ILCA bring to this project are expected to result in a successful California cannabis operation based in the City of San Diego.”

The MPF encompasses 10,700 square feet and will feature state-of-the-art technology for cultivation, production and distribution. A complex, sophisticated, portable racking system will create a 10,000 square foot canopy that has the potential to produce over 6,000 pounds of product per year with the help of high efficiency LED lights. The production sector of the MPF will deliver a large variety of cannabis-derived offerings such as flowers, pre-rolls, infused edibles, and topicals. Stem expects production from the MPF to begin during the fourth quarter of 2019.

ABOUT STEM HOLDINGS, INC.

As a vertically integrated cannabis company, Stem has positioned itself as a pioneer in the industry with its state-of-the-art cultivation, processing, extraction, retail, and distribution operations. Stem owns cannabis facilities in Nevada, Oklahoma, and Oregon, and also participates in a research project in collaboration with Cornell University. Utilizing proprietary, sustainable cultivation techniques, Stem develops exceptional products that are safe and consist of lab-tested cannabis and CBD. Stem’s partner consumer brands are award-winning and nationally known, and include: cultivators, TJ’s Gardens and Yerba Buena; retail brands, Stem and TJ’s; infused product manufacturers, Cannavore and Supernatural Honey; and a CBD company, Dose-ology. Stem’s mission in supporting the health and happiness of people and the safety of our planet is evident through the Company’s continued recognition for its community involvement, employee diversification and a top place to work in cannabis, dedication to environmental causes and outstanding leadership in the cannabis industry.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the management of Stem with respect to future business activities. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and include information regarding: (i) the ability to construct and operate the MPF and the financing sources therefor; (ii) plans relating to the distribution of products from the MPF; (iii) expectations for other economic, business, and/or competitive factors; (iv) the purchase price and closing date for the WCV acquisition; and (v) expectations around timing of the construction of the MPF, the features and attributes of the MPF, the timing of the commencement of production from the MPF, and the types of products to be produced from the MPF.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the management of Stem’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Stem believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; construction delays; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; adverse changes in the application or enforcement of current laws, including those related to taxation; the inability to locate and acquire suitable companies, properties and assets necessary to execute on the Company’s business plans; political risk; and increasing costs of compliance with extensive government regulation. This forward-looking information may be affected by risks and uncertainties in the business of Stem and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Stem has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Stem does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has in any way passed upon the merits of the proposed transactions described in this news release or has approved or disapproved of the contents of this news release.

For further information, please contact:

Media Contact:
Mauria Betts
Director of Branding and Public Relations
(971) 266-1908
mauria@stemholdings.com

Vancouver, British Columbia–(Newsfile Corp. – April 4, 2019) – Asterion Cannabis Inc. (P.ASTR) (“Asterion“) and PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announce today that Asterion’s wholly-owned Australian subsidiary, Asterion Australia Pty Ltd, has been awarded Major Project Status for Asterion’s Toowoomba Medicinal Cannabis Project (the “Toowoomba Project” or the “Facility”) by the Australia Federal Government.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com

Asterion:

Investor Relations
info@asterioncannabis.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the construction of the Facility and the implementation date and capital costs in connection therewith, the development functionality, productivity, production capacity and features of the Facility and the efficacy, consistency and quality of the cannabis products produced at the Facility, including the products used in PreveCeuitcal’s Sol-gel System, the outcome and success of the Toowoomba Project and the Sol-gel System, the workforce requirements to operate the Facility, matters related to Asterion and PreveCeutical’s current and planned projects and programs, including the Toowoomba Project and the Sol-gel program, and Asterion and PreveCeutical’s anticipated business plans and prospect of success in executing each of their plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes”, “estimates” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the inability of Asterion and PreveCeutical to, among other things, successfully carry out the Toowoomba Project and construct the Facility and obtain the required regulatory approvals and financing required for same, execute their proposed business plans and obtain the financing required to carry out planned future activities. Other factors such as general economic, market or business conditions, future prices of cannabis, changes in the financial markets and in the demand and market price for cannabis, or changes in laws, regulations and policies affecting the biotechnology or medical cannabis industry and delays in obtaining governmental and regulatory approvals, including for the Toowoomba Project and the Sol-gel program, may also adversely affect the future results or performance of Asterion and PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, neither Asterion nor PreveCeutical assumes any obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although Asterion and PreveCeutical believe that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by Asterion and PreveCeutical from time-to-time.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

TALLAHASSEE, FL, April 4, 2019 /CNW/ – Leading national cannabis company Trulieve Cannabis Corp. (“Trulieve”) (CSE: TRUL) announced today that it has signed an agreement with California-based Blue River Extracts & Terpenes (“Blue River”) to bring their award-winning terpene extracts and other trademark branded products to Florida’s growing patient base.

Blue River is an industry-leading cannabis company that has focused on the development of full spectrum solvent-less cannabis derived terpenes and began utilizing terpenes with advanced mechanical extraction techniques to create an array of award winning branded products including, Rosin, Dry Sift Sap, Vape Cartridges, CBD Crystalline, Rosin Sauce, THCa, Flan, and Jelly, which earned them over 50 cannabis awards to date. Blue River continued to shape the landscape of the cannabis industry through their proprietary solvent-less extraction technology and helped to popularize full-spectrum solvent-less products with the use of cannabis derived terpenes.

“Blue River has truly set the standard for innovation and excellence with their terpene technology, creating products that are high-quality and one-of-a-kind. Their dedication to quality, excellence, and standardization has changed the landscape of the cannabis market and matches Trulieve’s own dedication to the same standards,” said Trulieve CEO Kim Rivers. “Their products are an effective, reliable option for patients seeking relief in innovative ways.”

Blue River uses a proprietary extraction method to mechanically remove present terpenoids and cannabinoids from whole plant cannabis flowers without the use of any chemicals, solvents, or additives. The process results in clean, terpene-rich, high-quality products that provide the full potential of the plants medicinal value.  Once all regulatory approvals are obtained, a variety of Blue River terpene extracts, concentrates, and other products will be available exclusively in Florida through Trulieve. At this time, there can be no assurance as to the timing and scope of regulatory approval for the products, when and if it is obtained.

“Trulieve has an outstanding business model that relies on empowering diverse and gifted employees throughout the Florida market. Their attention to cultivation allows them to standardize high quality, indoor resin production, and in turn will allow for outstanding Blue River branded products. Trulieve has built a tremendous support system for Florida’s patients and I could not be more honored to work with them on this project,” said CEO Tony Verzura.

In stores and online, Trulieve provides patients with Florida’s largest selection of THC and CBD products, available in a variety of delivery methods, including whole flower, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients unable to make it to a physical store, in addition to 26 dispensaries in locations from Pensacola to Miami.

Recently, the Office of Medical Marijuana Use announced the registry had surpassed. 200,000 qualified patients with an active ID card in Florida, with Trulieve consistently selling a minimum of 60% of the state’s overall volume, per the Florida Department of Health. There are over 2,100 registered ordering physicians in the state of Florida as well.

To learn more about Trulieve, visit www.Trulieve.com.

About Trulieve
Trulieve Cannabis Corp. is a vertically integrated “seed to sale” company and is the first and largest fully licensed cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California and Massachusetts.

Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.

About Blue River
We believe in a farm-to-table model of cannabis extractions and enhanced terpene-rich products. Our proprietary extraction techniques allow us to separate terpenes and cannabinoids without damaging the integrity of the compounds, resulting in the cleanest, highest testing, and finest solvent-less products available in today’s market. Dedicated to providing quality, excellence, and standardization, Blue River has set the standard for innovation and excellence in terpene technology, effectively leading the way for new products and innovation on a global scale.

Regarding Forward-Looking Information
This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include, but are not limited to, statements regarding the anticipated benefits of the relationship between Blue River and Trulieve, the receipt of anticipated regulatory approvals and ultimate sale of Blue River products in Trulieve dispensaries, and the anticipated growth of the Florida medical cannabis market generally. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Neither Blue River nor Trulieve is under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Trulieve Cannabis Corp.

For further information: Lynn Ricci, Director of Investor Relations, (850) 480-7955, IR@trulieve.com; Victoria Walker, Director of Marketing & Community Relations, (704) 773-3446, Victoria.Walker@trulieve.com

MONTRÉAL, April 04, 2019 (GLOBE NEWSWIRE) — LGC Capital Ltd. (TSXV: LG, OTCQB: LGGCF) (“LGC”) is pleased to announce that is has been advised that Global Canna Labs has now received their formal approvals late in March from the Jamaican Cannabis Licensing Agency (CLA) to commence commercial medical cannabis sales domestically to licensed dispensaries.

As of today, Global Canna Labs has now sold a total of 46.5 kilograms of dried medical cannabis products in to the local dispensaries. It is now receiving regular domestic sales inquiries and demand for Global Canna Labs’ products is expected to accelerate from here.

LGC also advises that Global Canna Labs has now planted out the majority of its 6.2 acre site in Montego Bay and expects to commence harvesting, under CLA supervision, two sectional harvests per months from various phases of crop growth and various Cannabis strains, with the first of these bi-monthly harvests scheduled for April 10.

Global Canna Labs is one of the very few Tier-3 licences in Jamaica for the cultivation and production of medical cannabis (licensed to cultivate and produce over 5 acres), after formally receiving its full approval for a Tier-3 cultivation license from the Jamaican Cannabis Licensing Agency (“CLA”) in July 2018. This license allows GCL to cultivate medical cannabis at its 6.23 acres site in Montego Bay in Jamaica. GCL is planning on opening 2 Dispensaries and an Extraction facility in the very near future.

Mazen Haddad, Co-Chairman and CEO of LGC Capital, stated: “This is a tremendous achievement for the team in Jamaica. We have seen many achievements within Global Canna Labs since LGC became a cornerstone funder of this exciting company. We see them continuing to expand and grow at their facility in Montego Bay, as the market demand grows. Senior LGC management recently toured the Montego Bay facility to witness operations almost at full planting capacity and witnessed the results of the first harvests. There is still scope to infill sections of the 6.2 acre site before looking to expand beyond the existing secured growing areas. We see Jamaica as a very key growth market in the area and can see considerable expansion opportunities for Global Canna Labs as a Jamaican leader in their field, as the domestic and internal markets for Jamaica’s special brand of organic sativa strains and find their place in the market.”

LGC has a secured debenture, convertible into a 30% strategic interest in Global Canna Labs and a 5% royalty on Global Canna Labs’ net sales.

About LGC Capital:

Through its partners and assuming pending transactions under review by the TSXV are approved, LGC presently will have interests in over 450,000 square feet of planted cannabis in Jamaica, Switzerland, Italy, and Australia. That is expected to increase to over 2,100,000 square feet by 2021, as its portfolio companies execute their expansion plans, in addition to the anticipated licensing of Tricho-Med’s operations in Quebec, Canada.

LGC partners currently sell cannabis products in over 1,000 points of sale across Switzerland and Italy under the ONE Premium Cannabis and EasyJoint brands as well as medical cannabis oils in Australia under the Little Green Pharma brand. LGC’s partners’ branded products are available in a variety of formats including dry cannabis flower, tinctures, oils, seeds, and beverages.

For further information please contact:

John McMullen, President LGC Capital Ltd, +1-416-803-0698, john@lgc-capital.com
Investor Relations, Dave Burwell, +1-403-221-0915, dave@howardgroupinc.com

Notice Regarding Forward Looking Statements

This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”) and their respective operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward- looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC and Global Canna Labs (“GCL”) could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2018, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor GCL has any obligation to update such statements, except to the extent required by applicable securities laws.  Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

VANCOUVER and TORONTO, April 4, 2019 /CNW/ – AgraFlora Organics International Inc.  (“AgraFlora” or the “Company“) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF), a growth oriented and diversified international cannabis company, and Relay Medical Corp. (“Relay“) (CSE: RELA, OTCQB: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, jointly referred to as the “Partners“, are pleased to announce the execution of a binding letter of intent (“LOI“) to bring Glow LifeTech Ltd. (“Glow“), the cannabis technology joint venture, public by way of reverse takeover. In December 2018 the Partners jointly announced the formation of Glow to identify and develop technologies within the global cannabis sector.

“Our initial due diligence into the cannabis technology sector has indicated there is significant demand for new technologies in all levels of the emerging cannabis marketplace,” said Derek Ivany, President and CEO, AgraFlora Organics International. “AgraFlora’s first venture in cannabis related technology resulted in successful spin-off of the now publicly traded Cannvas MedTech to the benefit of shareholders. Taking Glow LifeTech public through a reverse takeover will provide the company with necessary capital to bring new and proprietary technology to market, again to the benefit of all shareholders. I look forward to working with the leadership team to execute on an aggressive business strategy and finalizing the proposed transaction with Ateba.”

The above-mentioned LOI is to be followed by a formal definitive agreement with Ateba Resources Inc. (“Ateba“) whereby Ateba will acquire all the securities of Glow by way of a share exchange, amalgamation or other transaction, subject to the terms and conditions of the LOI (the “Proposed Transaction“). The definitive agreement will be filed under Ateba’s profile on SEDAR at www.sedar.com. Pursuant to the terms of the Proposed Transaction, Ateba will change its name to Glow LifeTech Corp.  As a result of the Proposed Transaction, Ateba will continue on with the business of Glow.  Glow is responsible for a termination fee of $100,000 in the event Glow breaches the terms of the LOI. Ateba has no commercial operations, no assets and minimal liabilities.

Under the terms of the LOI, Glow will complete a minimum financing of $500,000 through the issuance of 2,500,000 common shares prior to the closing of the Proposed Transaction.  Additionally, Ateba will complete a 1.5555555 for 1 share consolidation prior to the closing of the Proposed Transaction.

Glow is currently owned 63.5% by Relay and 36.5% by AgraFlora.  With initial funding of at least $500,000 prior to the closing of the Proposed Transaction, Glow will establish its operational structure with a mandate to find and identify appropriate technology opportunities within the cannabis sector. Glow has commenced initial due diligence on industry related innovative technologies. After the completion of the Proposed Transaction and the contemplated listing, Glow will be positioned to advance and fund its business model with access to public capital markets.

Resulting Capitalization

After completion of the Proposed Transaction, and assuming no further common shares are issued, an aggregate of 15,500,000 common shares in the capital of Ateba (the “Ateba Shares“) will be issued and outstanding, with former securityholders of Glow holding 12,500,000 Ateba Shares, representing approximately 80% of the total outstanding Ateba Shares and the original shareholders of Ateba holding 3,000,000 Ateba Shares, representing approximately 20% of the outstanding Ateba Shares. The closing date for the Transaction is expected to be on or around June 30, 2019.

Management and Board of Directors

Upon completion of the Proposed Transaction, the board of directors and management of the resulting issuer will consist of the persons identified below:

W. Clark Kent – President & Chief Executive Officer, Director

Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the natural resources, technology and life science industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace. Since January 2018 Clark has served as President of MedTech accelerator Relay. Clark began his career with a boutique investment firm where he focused on client relations and marketing.

Chris Hopkins – Chief Financial Officer

Chris has over 25 years of leadership and financial management experience in the capital markets. He has spent most of his career in senior roles with public mining companies, including U.S. Silver, Rio Algom, BHP Billiton, Suncor and several Canadian and international companies. He has a Bachelor of Commerce from the University of Toronto, and a Chartered Accountant designation and MBA from the Schulich School of Business at York University.

Derek Ivany – Director

Mr. Derek Ivany was appointed President and Chief Executive Officer of AgraFlora in April 2016 and was instrumental at leading the company away from its resource past to become a large-scale cannabis producer on the world stage. As a public company consultant, Mr. Ivany has worked with numerous publicly traded companies across many different industries. He began his career in investor relations, marketing and corporate development in the oil & gas industry. He transitioned into the junior resource and mining section and most recently to technology and cannabis industries where he has continued to excel. Mr. Ivany continues to be active in both private and public capital markets and is considered an international influencer in the emerging global cannabis industry.

Medhanie Tekeste – Director

Mr. Tekeste is an executive with over 20 years of information systems experience including many years of broad-based management expertise in systems development, implementation and support. He is experienced in strategically and cost effectively utilizing technology to achieve corporate goals. He has extensive global experience in service delivery in the pharmaceutical industry including Quality, Manufacturing and R&D processes. Medhanie also has considerable experience in laboratory quality assurance testing and computer systems validation. Currently, he is the Chief Information Officer at Apotex Inc., where he is responsible for delivery of all end to end IT services globally, including Enterprise Architecture, Cloud and platform services, Service Design, Data Governance, Software Quality Assurance and Security Management, Governance, Program Management and Business Enablement.

Chris Irwin – Director

Chris Irwin practices securities and corporate/commercial law and has been the managing partner of Irwin Lowy LLP since January 2010; prior thereto he was the President of Irwin Professional Corporation from August 2006 to December 2009; and prior thereto he was an associate at Wildeboer Dellelce LLP from January 2004 to July 2006.  Mr. Irwin advises a number of public companies, board of directors and independent committees on a variety of issues.  Mr. Irwin is a director and/or officer of a number of public companies.  Mr. Irwin is a former Director of Trelawney Mining and Exploration Inc., a company acquired by IAMGOLD Corporation in a $608 million transaction; former Director of Southern Star Resources Inc., which was formerly listed on TSX prior to becoming Gold Eagle Mines Ltd. and being taken over by Goldcorp Inc. in a $1.5 billion transaction.

Ateba Resources Inc.

Ateba is a reporting issuer in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec and its common shares (the “Ateba Shares“) are not currently listed on any exchange or market.  The Company will provide an update on the Proposed Transaction and public listing process in a press release at a later date.

Glow LifeTech Ltd.

Glow is a private company founded by Relay and AgraFlora in December 2018 to pursue technology opportunities in the global cannabis sector. The newly formed entity combines Relay’s techno-commercial leadership with AgraFlora’s accumulated knowledge, expertise and access to cannabis industries across the sector. Glow will benefit from Relay’s infrastructure, technical leadership and business knowledge for the research, vetting, product development and validation of innovative technologies and AgraFlora will support the Company in the pursuit of technology opportunities in scientific validation, diagnostics, health & safety, screening, compliance and quality control/assurance within the cannabis industry.

About Relay Medical Corp.

Relay is an evolving “Integrated MedTech Accelerator” headquartered in Toronto, Canada, acquiring early-stage technologies and inventions, advancing and preparing them for pre-commercial acquisitions in the HealthTech marketplace. By integrating the funding, development and exit process into one organization led and managed by one expert team, Relay is building the capacity to accelerate and transact technologies with high efficiency and grow into a leading engine for MedTech innovation in the global HealthTech marketplace.

For more information visit: www.relaymedical.com

About AgraFlora Organics International Inc.

AgraFlora is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Service Canada and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry.

For more information please visit: www.agraflora.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for UXD described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com

SOURCE AgraFlora Organics International Inc.

For further information: Relay Medical Corp., W. Clark Kent, President, Relay Medical Corp., Office. 647-872-9982 ext. 2, TF. 1-844-247-6633 ext. 2, investor.relations@relaymedical.com; Bernhard Langer, EU Investor Relations, Office. +49 (0) 177 774 2314, Email: blanger@relaymedical.com; AgraFlora Organics International Inc., Tim McNulty; For additional information: E: ir@agraflora.com, T: (800) 783-6056

Related Links

https://www.agraflora.com/

VANCOUVER, April 3, 2019 /CNW/ – AgraFlora Organics International Inc. (CSE: AGRA) (Frankfurt: PU3) (OTC: PUFXF), and Liberty Leaf Holdings Ltd. (CSE: LIB) (OTC: LIBFF) (Frankfurt: HN3P) together, (“the Companies“), are pleased to announce that, further to the joint news release of September 20, 2018, the Companies have made significant advancement with respect to gaining entry into the medical cannabis market in the European Union and, as such, have formed a jointly owned Greek company, AgraLeaf SA (“AgraLeaf“), so as to formally capitalize on the opportunity. AgraFlora and Liberty Leaf will own an equal equity stake in AgraLeaf with specific details regarding the obligations of the Companies to be outlined in a shareholder’s agreement.  AgraLeaf has established a team in Greece consisting of personnel with expertise in commercial horticulture, government affairs, legal and finance.

“The new joint venture company will provide access for our shareholders to participate in one of the largest medical cannabis markets in the world,” said Derek Ivany, President and CEO, AgraFlora Organics International Inc. “We have assembled an experienced local management team in Greece and I am confident they possess the skillsets necessary to ensure our success. I look forward to working with Will and the team at Liberty Leaf as we advance this significant opportunity to the mutual benefit of all stakeholders.”

“Having just returned from a due diligence trip, I am extremely impressed with the opportunities for large-scale cannabis cultivation that Greece affords,” said Will Rascan, President and CEO of Liberty Leaf. “AgraFlora has established themselves as capable operators in the burgeoning cannabis marketplace and we are excited about the prospects of working alongside their team as we pursue this exciting new venture in Greece.”

The fertile agricultural regions of Greece combined with relatively low-cost labor and property prices make it a prime locale for large-scale medical cannabis cultivation.  In November 2018, Greece issued the first licenses to private companies for growing medicinal cannabis.  As a gateway to the European Union, which is home to more than 500 million people, AgraLeaf will thus be granted access to this significant piece of the globalized cannabis market. Recent research reports by Prohibition Partners have estimated that the cannabis market in the EU may represent as much as €123 billion by 2028.

Additional updates and details will be provided in due course as AgraLeaf progresses through the licensing application process.

About Agraflora Organics International Inc.

Agraflora Organics International is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, Ont., and is a joint venture partner in Propagation Service Canada and its large-scale 2.2-million-square-foot greenhouse complex in Delta, B.C. The company has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.

About Liberty Leaf Holdings Ltd.

Liberty Leaf Holdings Ltd. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of cannabis-sector businesses, including cultivation, processing, value-added CBD/THC products and supply-chain products within this dynamic and fast-growing sector. For more information please visit: www.libleaf.com.

ON BEHALF OF THE BOARD OF DIRECTORS OF AGRAFLORA ORGANICS INTERNATIONAL INC.,

Derek Ivany
President & CEO

ON BEHALF OF THE BOARD OF DIRECTORS OF LIBERTY LEAF HOLDINGS LTD.,

Will Rascan
President & CEO

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The Company disclaims any intention or obligation to revise or update such statements.

SOURCE AgraFlora Organics International Inc.

For further information: AgraFlora Organics International Inc., Tim McNulty, E: ir@agraflora.com, T: (800) 783-6056; For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI; Liberty Leaf Holdings Ltd., Phone: 778-819-0244, Toll Free: 1-833-LIB-LEAF (542-5323); Twitter: @LibertyLeafCSE, Facebook: LibertyLeafCSE